Taconic Biosciences and Cellaria Biosciences Agree to Scientific Collaboration to Facilitate Xenograft Use in Oncology Research Taconic Biosciences and Cellaria Biosciences announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts in animal models for oncology and immuno-oncology research. [Taconic Biosciences, Inc.] Press Release Novasep and Celladon Execute MYDICAR API Supply Agreement Novasep and Celladon Corporation announced that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020. [Novasep] Press Release RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi’s Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-Based Immunotherapies to Treat Cancer RXi Pharmaceuticals Corporation and privately-held MirImmune LLC, announced that they have entered into an exclusive license agreement to RXi’s novel and proprietary sd-rxRNA® technology for use in developing innovative cell-based cancer immunotherapies. [RXi Pharmaceuticals Corporation] Press Release Accellta Grants Exclusive Rights for Micro-Carrier Free Stem Cells Suspension Culture to STEMCELL Technologies The stem cell company Accellta announced that it has granted exclusive worldwide rights to STEMCELL Technologies Inc. for manufacturing and distribution of medium for culturing pluripotent stem cells in suspension under feeder-free, non-adherent conditions. [Accellta Ltd.] Press Release apceth Initiates Phase II Clinical Trial for Pioneering Engineered Cell Therapy to Treat Gastrointestinal Cancer apceth announced the successful completion of the Phase I and initiation of the Phase II part of its ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T. [apceth GmbH & Co. KG] Press Release Medigene Starts Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukemia (AML) Medigene AG announced that the company’s Phase I/II clinical trial with its dendritic cell vaccine for the treatment of AML has started. [Medigene AG] Press Release Immunovaccine Initiates Phase II Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma Immunovaccine Inc. announced that it has treated the first patient with diffuse large B cell lymphoma in a Phase II clinical study of its lead cancer immunotherapy DPX-Survivac. [Immunovaccine Inc.] Press Release UC Researchers Awarded Stem Cell Grants University of California researchers from two campuses received three grants totaling more than $12 million in funding from the state’s stem cell agency to develop stem cell treatments for Huntington’s disease, spina bifida and chronic diabetic wounds. [UC Health] Press Release City of Hope Launches Stem Cell Therapy Clinic to Fight Incurable Disease in New Ways The City of Hope officially opened the Alpha Clinic for Cell Therapy and Innovation for patients battling cancer and other life-threatening diseases. The Alpha Clinic is funded by an $8 million, five-year grant from the California Institute for Regenerative Medicine that will be supplemented by matching funds from City of Hope. [City of Hope] Press Release Researchers Aim to Broaden Understanding of How Toxins Affect the Body University of Wisconsin-Madison researchers received $6 million from the U.S. Environmental Protection Agency to develop models and screening tools that will rapidly advance knowledge of the health effects of an ever-growing assortment of environmental toxins. Awarded through the EPA Science to Achieve Results program, the grant will create the Human Models for Analysis of Pathways Center at UW-Madison. [University of Wisconsin-Madison] Press Release |